We are live on ! Find out more
VIRX

Viracta Therapeutics, Inc. Common Stock
VIRX

Delisted

VIRX was delisted on the 3rd of February, 2025.

Back to rankings

75 hedge funds and large institutions have $180M invested in Viracta Therapeutics, Inc. Common Stock in 2013 Q2 according to their latest regulatory filings, with 75 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.

New
Increased
Maintained
Reduced
Closed

92% less call options, than puts

Call options by funds: $209K | Put options by funds: $2.58M

Holders
75
Holders Change
+75
Holders Change %
–
% of All Funds
2.45%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
75
Increased
–
Reduced
–
Closed
–
Calls
$209K
Puts
$2.58M
Net Calls
-$2.37M
Net Calls Change
-$2.37M

Top Buyers

No buyers this quarter

Top Sellers

No sellers this quarter
Name Holding Trade Value Shares
Change 		Change in
Stake
TCIM
26
TIAA CREF Investment Management
New York
$645K +$656K +589 New
Allianz Asset Management
27
Allianz Asset Management
Germany
$597K +$611K +548 New
MOACM
28
Mutual of America Capital Management
New York
$591K +$602K +540 New
Deutsche Bank
29
Deutsche Bank
Germany
$581K +$597K +536 New
California Public Employees Retirement System
30
California Public Employees Retirement System
California
$532K +$543K +487 New
DL
31
Delta Lloyd
Netherlands
$519K +$530K +476 New
AIG
32
American International Group
New York
$516K +$528K +474 New
BIM
33
BlackRock Investment Management
Delaware
$442K +$452K +406 New
HVC
34
Healthcare Value Capital
New Jersey
$432K +$441K +396 New
RFC
35
Russell Frank Company
Washington
$426K +$435K +390 New
AQR Capital Management
36
AQR Capital Management
Connecticut
$396K +$403K +362 New
Principal Financial Group
37
Principal Financial Group
Iowa
$394K +$401K +360 New
MCM
38
Munder Capital Management
Michigan
$346K +$354K +318 New
D.E. Shaw & Co
39
D.E. Shaw & Co
New York
$332K +$338K +303 New
Charles Schwab
40
Charles Schwab
California
$321K +$309K +277 New
CS
41
Credit Suisse
Switzerland
$306K +$314K +282 New
PA
42
Perceptive Advisors
New York
$301K +$308K +276 New
California State Teachers Retirement System (CalSTRS)
43
California State Teachers Retirement System (CalSTRS)
California
$294K +$299K +268 New
TD Asset Management
44
TD Asset Management
Ontario, Canada
$284K +$290K +260 New
Bank of Montreal
45
Bank of Montreal
Ontario, Canada
$265K +$271K +243 New
Ameriprise
46
Ameriprise
Minnesota
$232K +$236K +212 New
TA
47
Teachers Advisors
New York
$229K +$233K +209 New
VOYA Investment Management
48
VOYA Investment Management
Georgia
$200K +$204K +183 New
Royal Bank of Canada
49
Royal Bank of Canada
Ontario, Canada
$194K +$197K +177 New
BJ
50
BlackRock Japan
Japan
$179K +$183K +164 New
1
2
3

VIRX Hedge Fund Activity: Q2 2013 in Review

75 of the 3,065 institutional investors tracked by Wall St. Rank reported a position in Viracta Therapeutics, Inc. Common Stock (VIRX) for Q2 2013, worth a combined $180M.

Buyers outnumbered sellers: 75 funds opened new VIRX positions and 0 closed out — a net gain of 75 holders — while 0 added to existing stakes and 0 trimmed.

  • 75 institutional investors held Viracta Therapeutics, Inc. Common Stock (VIRX) as of Q2 2013, up from 0 in Q1 2013.
  • Funds reported $180M of Viracta Therapeutics, Inc. Common Stock stock for Q2 2013.
  • 75 funds opened new Viracta Therapeutics, Inc. Common Stock positions in Q2 2013 and 0 closed out, a net change of +75 holders.

Based on aggregated 13F filings for Q2 2013.